What is the true prevalence of EGFR mutations in India?

Lung Cancer

Volumn 74, Issue 3, 2011, Pages 549-

  Jiwnani, Sabita ^a   Karimundackal, George ^a   Pramesh, C S ^a   Prabhash, Kumar ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

EGFR mutation; Prevalence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ASIAN; CANCER EPIDEMIOLOGY; CAUCASIAN; COST; CYTOLOGY; GENE MUTATION; HISTOLOGY; HUMAN; INDIA; LETTER; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80755139457     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.09.013     Document Type: Letter

References (4)

1. Sahoo R., Vidya Harini V., Chitti Babu V., Patil Okaly G.V., Rao S., Nargund A., et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 2011, 73:316-319.
2. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl J Med 2010, 362:2380-2388.
3. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med 2009, 361:947-957.
4. Behera D., Balamugesh T. Lung cancer in India. Indian J Chest Dis Allied Sci 2004, 46:269-281.